Table 2.
Diabetes status among cohort patients before they acquired COVID-19 (n=103).
| Item | Value, n (%) | |
| Type of diabetes or dysglycemic status | ||
|
|
Type 1 | 3 (2.9) |
|
|
Type 2 | 90 (87.4) |
|
|
Prediabetes | 10 (9.7) |
| Diabetes and dysglycemic status |
|
|
|
|
Known | 88 (85.4) |
|
|
Unknown | 15 (14.6) |
| Control of diabetes |
|
|
|
|
Controlled (HbA1ca<7.5%) | 46 (44.6) |
|
|
Not controlled (HbA1c≥7.5%) | 52 (50.4) |
| Diabetes medications taken prior to admissionb |
|
|
|
|
Sulphonylurea | 17 (16.5) |
|
|
Metformin | 64 (62.1) |
|
|
Acarbose | 1 (0.9) |
|
|
DDP-4c inhibitor | 4 (3.9) |
|
|
SGLT-2d inhibitor | 5 (4.9) |
|
|
GLP-1e receptor agonist | 1 (0.9) |
|
|
Basal insulin | 8 (7.8) |
|
|
Basal-bolus insulin | 6 (5.8) |
| Insulin dose (units) in 24 h, mean (SD) | 73.4 (33.7) | |
aHbA1c: hemoglobin A1c.
bThe same patient could have received more than one medication.
cDDP-4: dipeptidyl peptidase-4 inhibitor.
dSGLT-2: sodium-glucose co-transporter-2.
eGLP-1: glucagon-like peptide 1.